Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …

PURPOSE Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large
B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship …

Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …

Accurate prediction of long-term outcomes remains a challenge in the care of cancer
patients. Due to the difficulty of serial tumor sampling, previous prediction tools have focused …

Response is the logical outcome measure of a treatment in a clinical or research setting.
Objective response assessment involves the use of a test to segregate patients who are …

Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70%
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …

Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative
disorders characterized by different clinical courses, varying from indolent to highly …

PET/CT molecular imaging has been imposed in clinical oncological practice over the past
20 years, driven by its two well-grounded foundations: quantification and radiolabeled …